Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC62H63F2N7O12S |
InChIKeyLYUUIIZKBMBNQV-CHOFKVETSA-N |
CAS Registry2254609-23-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 10 Jan 2019 | |
Neoplasms | Preclinical | US | 10 Jan 2019 |